Category: Prostate Cancer

When it comes to diagnosing localized prostate cancer (PCa), there’s the old world and the new world. Localized PCa means the disease is still contained in the prostate gland at the time of treatment. This knowledge is a crucial key to wise treatment decisions, especially radical treatments aimed at removing or destroying the entire gland. keep reading

According to cancer.net, “A cancer diagnosis often brings concerns about how long your life will be.” Even though prostate cancer (PCa) is not as life-threatening as some other tumor cancers, PCa patients who have just been diagnosed may still encounter fear of death. Yet, the odds of dying from something other than their cancer are keep reading

“Overall, African American men are 1.8 times more likely to be diagnosed with—and 2.2 times more likely to die from—prostate cancer than white men.” (From ZERO The End of Prostate Cancer) This point blank statement is the result of statistics that have remained fairly consistent over recent decades. This data has been the basis for keep reading

Once upon a fairly recent time, radical prostatectomy (RP) was the treatment of choice for prostate cancer (PCa), even for high risk disease. There were two main reasons for this: It was believed that PCa was a multifocal disease scattered throughout the gland, even if too small to be picked up by biopsy. Therefore, aggressively keep reading

We have occasionally posted blogs about the grassroots influence that prostate cancer (PCa) patients can have over trends in PCa treatment. For example, patient desire and demand for less invasive treatments that can diminish their quality of life played an enormous part in the evolution of focal therapies, such as our own Focal Laser Ablation. keep reading

Patients who choose robotic-assisted radical prostatectomy (RARP) believe it’s the best way to eradicate prostate cancer (PCa). In their mind, this equates to a cure. In fact, PCa can recur (come back) as long as 15 or more years after any whole-gland treatment. Increasingly, no one talks about “cure” anymore. Instead, “success” is defined as keep reading

Do you ever regret a decision that turns out to have a bad outcome? This is the situation for many prostate cancer (PCa) patients who chose radical prostatectomy (RP). A 2017 study found that 15% of PCa patients regret their treatment choice, with twice as many patients ruing the day they opted for RP or keep reading

The tug-of-war continues between prostate cancer patients who want to be treated with proton beam therapy (PBT) vs. their insurance companies. As you can read from the blog below, payers are denying PCa coverage due to the high cost of the treatment coupled with lack of evidence showing superiority over conventional radiation therapies... keep reading

Here’s the back story: there is a British clinician/researcher, Hashim Ahmed, whose published articles I respect. His publications often include Mark Emberton, another esteemed British urologist, so when both names turn up in the same group of authors on a published paper, it grabs my attention. This is the case with a 2020 multicenter study keep reading

There’s an exciting new development in treating metastatic prostate cancer (PCa) that no longer responds to hormone therapy. Such cancer is clinically called metastatic castration-resistant prostate cancer, or mCRPC. There is currently no cure when PCa reaches this stage, but new drugs and immunotherapies can prolong life. Researchers are exploring and testing therapies that destroy keep reading